Georgia's Online Cancer Information Center

Find A Treatment Site

Winship Cancer Institute of Emory University

Winship Cancer Institute NCI Designated Comprehensive Cancer Center
Winship Cancer Institute of Emory University
Atlanta, Georgia

Winship Cancer Institute of Emory University is Georgia's first and only comprehensive cancer center designated by the National Cancer Institute (NCI). Designation requires meeting rigorous criteria for the depth and breadth of basic science and clinical research, in addition to cancer prevention, control, and population/behavioral sciences. It requires effective collaboration among various disciplines and with community partners in private practice and in academic centers throughout Georgia and across the nation. With this recognition comes the responsibility to provide public information, education and outreach to other health care professionals and the community. NCI designation for Winship gives Georgians improved access to clinical trials and resources that may not be available elsewhere.

The Winship Cancer Institute (Winship) at Emory University is a multidisciplinary matrix center that supports, facilitates, coordinates, and centralizes cancer research, quality oncology care, education, and dissemination at Emory University and its affiliate institutions in order to reduce the burden of cancer, associated morbidity, and mortality in the state of Georgia, the Southeastern region, and the U.S. Winship is dedicated to the integration of innovative clinical and basic science research with outstanding patient care for the prevention, treatment and control of cancer.

1-888-946-7447
winshipcancer.emory.edu

Treatment Sites in Georgia

Primary Location

1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-1900 (p)
winshipcancer.emory.edu

driving directions

Doctors

Abeer N. AbouYabis MD
Nazmi Volkan Adsay MD
Michael R. Aho MD
Mehmet Akce MD
Mehrdad Alemozaffar MD
Olatunji B. Alese MD
Olatunji B. Alese MD
Pamela Blair Allen MD, MSc
Ana Antun MD
Jack Arbiser MD, PhD
Cletus A. Arciero MD
Martha L. Arellano MD
Bruce J. Barron MD
Deborah A. Baumgarten MD, MPH
Jonathan J. Beitler MD, MBA, FACR
Leon Bernal MD
George G. A. Birdsong MD
William G. Blum
Daniel J. Brat MD, PhD
Otis W. Brawley MD
Joan Cain MD, MSc
Grant W. Carlson MD
Bradley C. Carthon, MD, PhD
Amy Y. Chen MD
Cynthia Cohen MD
Jonathon B Cohen MD, MS
Michael A. Cohen MD, FACR
Laronna S Colbert MD
Ian R. Crocker MD, FACR
Walter J Curran, Jr. MD, FACR
Keith A. Delman MD, FACS
Maria Diab MD
Roberto R. Diaz MD
Scott H. Edelman MD
John William Eley MD, MPH
Bassel F El-Rayes MD
Tony Y Eng MD
Christopher R. Flowers MD
Sarah Friend MD
Sheryl A. Gabram-Mendola MD, MBA, FACS
Manila Gaddh , MD
Anthony Andrew Gal MD
Jacques Galipeau MD
Karen D. Godette MD
Keerthi Gogineni MD
Bruce D Goldsweig MD
Cathy L Graham MD, FACS
William J. Grist MD
Kathleen Gundry MD
Vikas A Gupta MD
Raghuveer K. Halkar MD
Chunhai Hao MD, PhD
Wayne B. Harris MD
R. Donald Harvey , PharmD
Natalyn N. Hawk MD
Leonard T. Heffner Jr., MD
Bruce W. Hershatter MD
Kristin Higgins MD
Charles E. Hill MD
Craig C Hofmeister MD, MPH
Chad A. Holder MD
Stephen B. Hunter MD
Sol Jacobs MD
Ashesh B. Jani MD
David L. Jaye MD
Jade Jones MD
Jonathan L. Kaufman MD
H. Jean Khoury MD, FACP
Kevin Kim MD
Adam M. Klein MD
Rebecca Bruner Klisovic MD
Jean L Koff MD
David A. Kooby MD
Vamsi K. Kota MD
Joan Kramer
Omer Kucuk MD
Ragini R Kudchadkar MD
J. David Lambeth MD, PhD
Jerome C. Landry MD
Amelia A. Langston MD
Stephen K. Lau MD
David H. Lawson MD
Mary Jo Lechowicz MD
Daniel J. Lee MD
Melinda Moore Lewis MD
Shiyong Li MD, PhD
Jolinta Y Lin MD
James V. Little MD
Sagar Lonial MD
Shishir K. Maithel MD
Anant Mandawat MD
Karen P. Mann MD, PhD
Viraj Master MD, PhD
Mark William McDonald MD
Morgan L. McLemore MD
Jane L Meisel MD
Daniel L. Miller MD
Leon Bernal- Mizrachi MD
David K Monson MD
Melvin Moore MD
Mario Mosunjac MD
Susan C. Muller DMD, MS
Padma C. Nadella MD
Mary S. Newell MD
Peter T. Nieh MD
Ajay K. Nooka MD, MPH
William O'Connell MD
Kenneth Ogan MD
Joel A Okoli MD MPH
Jeffrey J. Olson MD
Gabriela M. Oprea MD
Adeboye O. Osunkoya MD, FCAP
Taofeek K. Owonikoko MD
Nelson M. Oyesiku MD, PhD, FACS
Nicki Panoskaltsis MD, PhD, FRCP
Nicki Panoskaltsis MD, PhD, FRCP
Elisavet Paplomata MD
Douglas C. Parker MD
Pretesh Patel MD
Sagar A Patel MD
Allan Pickens MD
Rathi Pillai MD
Brian P Pollack MD, PhD
Suresh S. Ramalingam MD
William Read , MD
Satyanarayan K. Reddy MD
Nickolas B Reimer MD
Maria J. Ribeiro MD
Chad W Ritenour MD
Monica Rizzo MD
Steven M. Roser DMD, MD
Peter J. Rossi MD
Nabil F. Saba MD, FACP
Ruth Sacks MD
Manu S Sancheti
Martin G Sanda MD
Juan M. Sarmiento MD
Neil D Saunders MD
David M. Schuster MD
Judy H. Sequeira MD
Charles W. Sewell MD
Virginia O Shaffer MD
Mihir M Shah MD
Jyotirmay Sharma MD
Dong Moon Shin MD
Hui-Kuo G. Shu MD, PhD
Mark Shumate MD, MPH
Gabriel L. Sica MD
Momin T. Siddiqui MD, FIAC
William C. Small MD
Cyril O. Spann MD,SM, FACOG, FACS
Charles A. Staley MD
Liza J. Stapleford MD
Sidney F. Stein MD
Conor F Steuer
Toncred M. Styblo MD
Preeti D Subhedar MD, MSPT
Pakkala Suchita
Ajay Tadepalli MD
Talaat S. Tadros MD
Ahmad Tarhini MD, PhD
Meena Thirunavu MD
Mylin A. Torres MD
William E. Torres MD
Keriann M. Van Nostrand MD
Vijay Alluri Varma MD
Alfredo D. Voloschin MD
J. Trad Wadsworth MD
Edmund K. Waller MD, PhD, FACP
Mark D Walsh MD, FACS
Carl Washington MD
Sharon W. Weiss MD
Ifor R. Williams MD, PhD
Elliott F. Winton MD
Christina Wu MD
Howa Yeung MD
David Yu MD
Melinda L Yushak
Jim Zhong MD

Clinical Trials in Georgia

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type: Unknown Primary

9-ING-41 in Patients With Advanced Cancers
Cancer Type: Bladder Cancer, Bone Tumor, Brain & Spinal Cord Tumor, Breast Cancer, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma

A Comparison of Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Cancer Type: Solid Tumor, Unknown Primary

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
Cancer Type: Lung Cancer

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type: Hematopoietic Malignancies
Study Coordinator: Heather Renfroe - 404-778-5127


A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life
Cancer Type: Quality of Life
Study Coordinator: Heather Renfroe - 404-778-5127


A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Cancer Type: Lung Cancer, Solid Tumor, Unknown Primary

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type: Leukemia, Lymphoma

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma

A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type: Hematopoietic Malignancies, Solid Tumor

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Cancer Type: Non-Hodgkin Lymphoma

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Cancer Type: Prostate Cancer , Unknown Primary

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
Cancer Type: Leukemia

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Cancer Type: Head and Neck Cancer

A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Cancer Type: Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type: Multiple Myeloma

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Cancer Type: Melanoma

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Cancer Type: Leukemia, Lymphoma, Non-Hodgkin Lymphoma

A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma
Cancer Type: Gynecologic Cancers, Lung Cancer, Lymphoma, Neuroendocrine Tumor, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Cancer Type: Head and Neck Cancer, Neuroendocrine Tumor, Thyroid Cancer, Unknown Primary

A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation
Cancer Type: Leukemia

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Cancer Type: Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type: Colon/Rectal Cancer, Lung Cancer, Melanoma

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Cancer Type: Cervical Cancer, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Penile Cancer, Primary Peritoneal Cancer

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Cancer Type: Solid Tumor, Unknown Primary

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Cancer Type: Multiple Myeloma

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Cancer Type: Sarcoma

A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Cancer Type: Hematopoietic Malignancies, Unknown Primary

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Cancer Type: Bile Duct Cancer

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
Cancer Type: Hematopoietic Malignancies, Multiple Myeloma, Plasma cell neoplasm, Unknown Primary

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)
Cancer Type: Multiple Myeloma

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
Cancer Type: Brain & Spinal Cord Tumor, Lung Cancer, Solid Tumor, Unknown Primary

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Cancer Type: Hematopoietic Malignancies, Solid Tumor

AFP?³³²T in Advanced HCC
Cancer Type: Liver Cancer / Hepatoblastoma

An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50X10 9/L to 100 X 10 9L
Cancer Type: Symptom Management
Study Coordinator: Wilena Session - 404-778-5319


An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Cancer Type: Lung Cancer

An Open-Label, Single Arm, Phase 2 Study of Carfilzomib Maintenance Therapy in Subjects Previously in Enrolled Carfilzomib Treatment Protocols
Cancer Type: Multiple Myeloma

Atezolizumab and Cobimetinib in Treating Patients with Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients with Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma
Cancer Type: Cancer-Related Syndrome

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Cancer Type: Bile Duct Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Neuroendocrine Tumor, Ovarian Cancer, Pancreatic Cancer, Sarcoma

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Cancer Type: Breast Cancer, Cervical Cancer, Lung Cancer, Solid Tumor, Unknown Primary

Battery Powered Drill versus Conventional Methods in Comparing Quality of Bone Marrow Biopsy, Convenience, and Pain Control in Patients with Plasma Cell Disorders
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Bendamustine, Obinutuzumab, and Venetoclax in Treating Patients with Mantle Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Biopsy of Breast after Chemotherapy in Predicting Pathologic Response in Patients with Breast Cancer Undergoing Breast Conserving Surgery
Cancer Type: Breast Cancer

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia",
Cancer Type: Leukemia

Brentuximab Vedotin and Nivolumab in Treating Patients with Early Stage Classic Hodgkin Lymphoma
Cancer Type: Hodgkin Lymphoma

Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type: Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary

Cabozantinib and Pembrolizumab as First Line Therapy in Treating Patients with Cisplatin-Ineligible Metastatic, Locally Advanced, or Unresectable Urothelial Cancer
Cancer Type: Unknown Primary

Cabozantinib in Treating Patients with Locally Advanced Non-metastatic Kidney Cancer
Cancer Type: Kidney Cancer, Unknown Primary

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients with High-Risk Multiple Myeloma
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

CAR-T Long Term Follow Up (LTFU) Study
Cancer Type: Unknown Primary

Cemiplimab for the Treatment of Immunocompromised Patients with Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma
Cancer Type: Skin Cancer (Non-Melanoma), Unknown Primary

Chemoradiation with or without Atezolizumab in Treating Patients with Limited Stage Small Cell Lung Cancer
Cancer Type: Lung Cancer

Chemotherapy and Pelvic Radiation Therapy with or without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy
Cancer Type: Cervical Cancer
Study Coordinator: Dosha James - 404-778-5311


Chemotherapy before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients with Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Cancer Type: Head and Neck Cancer, Unknown Primary

Cholecalciferol in Improving Survival in Patients with Newly Diagnosed Cancer with Vitamin D Insufficiency
Cancer Type: Hodgkin Lymphoma, Leukemia, Lymphoma

Comparing Photon Therapy to Proton Therapy to Treat Patients with Lung Cancer
Cancer Type: Lung Cancer, Unknown Primary

Comparing Standard Treatment Alone to Radiation Therapy with or without Surgery with Standard Treatment for Patients with Limited Metastatic Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic therapy with either Surgery or Radiation Therapy, for Patients with Advanced Prostate cancer
Cancer Type: Prostate Cancer , Unknown Primary

Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Cancer Type: Lung Cancer

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule
Cancer Type: Solid Tumor, Unknown Primary

Daratumumab, Ixazomib, and Dexamethasone with or without Bortezomib in Treating Patients with Newly Diagnosed Multiple Myeloma
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Cancer Type: Liver Cancer / Hepatoblastoma

Dexamethasone, Carfilzomib, and Nivolumab with Pelareorep in Treating Patients with Relapsed Multiple Myeloma
Cancer Type: Multiple Myeloma

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients with Stage I-III Breast Cancer
Cancer Type: Breast Cancer

Docetaxel, Ramucirumab, and Pembrolizumab for the Treatment of Metastatic or Recurrent Non-small Cell Lung Cancer in Patients who have Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade Therapy
Cancer Type: Lung Cancer

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Cancer Type: Breast Cancer, Cervical Cancer, Esophogeal Cancer, Head and Neck Cancer, Hodgkin Lymphoma, Lung Cancer, Lymphoma, Stomach/ Gastric Cancer

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients with Stage I-II Hodgkin Lymphoma
Cancer Type: Hodgkin Lymphoma

DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

Durvalumab, MVA-BN-CV301, FPV Vaccine CV301, and Capecitabine with or without Bevacizumab in Treating Patients with Metastatic Colorectal or Pancreatic Cancer
Cancer Type: Colon/Rectal Cancer, Pancreatic Cancer, Unknown Primary

Dynamic Susceptibility Contrast MRI in Determining Radiation Necrosis and Tumor Progression in Participants with Cancer with Brain Metastases Treated with Stereotactic Radiation Therapy
Cancer Type: Brain & Spinal Cord Tumor, Unknown Primary

Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Cancer Type: Solid Tumor

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Cancer Type: Colon/Rectal Cancer, Pancreatic Cancer

Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type: Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma

Fatigue Assessment in Patients with Breast Cancer Undergoing Chemotherapy, Surgery, or Radiation Therapy
Cancer Type: Breast Cancer, Unknown Primary

Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Cancer Type: Hematopoietic Malignancies

First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Cancer Type: Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor

Fluciclovine (18F) PET/CT Imaging in Indicating Early Metastatic Disease in Patients with High or Unfavorable Intermediate-Risk Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET/CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma
Cancer Type: Prostate Cancer , Unknown Primary

Fulvestrant with or without Palbociclib and Avelumab in Treating Patients with Hormone Receptor Positive, HER2 Negative Metastatic or Recurrent Breast Cancer That Cannot Be Removed by Surgery Previously Treated with CDK and Endocrine Therapy
Cancer Type: Breast Cancer

Gemcitabine and Cisplatin with Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Cancer Type: Bile Duct Cancer

Gemcitabine, Bendamustine Hydrochloride, and Nivolumab in Treating Patients with Relapsed or Refractory Classic Hodgkin Lymphoma
Cancer Type: Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Cancer Type: Lung Cancer

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Cancer Type: Colon/Rectal Cancer, Lung Cancer, Pancreatic Cancer, Stomach/ Gastric Cancer

GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Cancer Type: Cervical Cancer, Lung Cancer

Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Cancer Type: Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Cancer Type: Unknown Primary

Hepatic Impairment Study for Lorlatinib in Cancer Patients
Cancer Type: Brain & Spinal Cord Tumor, Lymphoma

Hypofractionated Proton or Photon Radiation Therapy for the Treatment of Brain Tumors, the HiPPI Study
Cancer Type: Brain & Spinal Cord Tumor

ILND Surgery Alone or after Chemotherapy with or without Radiation Therapy in Treating Patients with Advanced Penile Cancer
Cancer Type: Penile Cancer

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Cancer Type: Hodgkin Lymphoma

Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Cancer Type: Head and Neck Cancer, Unknown Primary

Influenza Vaccination in Preventing the Flu in Patients with Plasma Cell Disorders
Cancer Type: Plasma cell neoplasm

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Cancer Type: Leukemia

Intensity Modulated Proton Therapy in Treating Younger Patients with Cancer of the Central Nervous System
Cancer Type: Brain & Spinal Cord Tumor

Intensity-Modulated Radiation Therapy and Nivolumab in Treating Participants with Recurrent or Second Primary Head and Neck Squamous Cell Cancer
Cancer Type: Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary

International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Cancer Type: Prostate Cancer

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Cancer Type: Breast Cancer

Ixazomib and Pevonedistat in Treating Patients with Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
Cancer Type: Multiple Myeloma

Ketorolac before Surgery for the Treatment of Stage I-II Non-small Cell Lung Cancer or Stage III Renal Cell Cancer
Cancer Type: Lung Cancer

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients with Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Cancer Type: Colon/Rectal Cancer

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Cancer Type: Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm, Solid Tumor

Low-Dose Radiation Therapy for the Treatment of Storming Cytokines and Unchecked Edema in Patients with COVID-19 Infection, RESCUE 1-19 Study
Cancer Type: COVID-19

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Cancer Type: Bone Tumor, Multiple Myeloma, Plasma cell neoplasm

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.
Cancer Type: Lung Cancer

N-803 in Preventing Relapse in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome That Have Undergone a Donor Stem Cell Transplant
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

NFKB2 Rearrangement in Guiding Treatment with Ixazomib Citrate and Dexamethasone or Ixazomib Citrate, Dexamethasone and Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Nivolumab and Degarelix with or without BMS-986253 in Treating Patients with Hormone-Sensitive Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Nivolumab and Ipilimumab in Treating Patients with Advanced Rare Genitourinary Tumors
Cancer Type: Adrenal Cancer, Bladder Cancer, Neuroendocrine Tumor, Penile Cancer, Prostate Cancer , Unknown Primary

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain Tumor, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Mesothelioma, Neuroendocrine Tumor, Ovarian Cancer, Parathyroid Cancer, Penile Cancer, Retroperitoneal Tumors, Sarcoma, Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer

Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Cancer Type: Hematopoietic Malignancies

Nivolumab with or without Ipilimumab as Front Line Therapy in Treating Patients with Advanced Kidney Cancer
Cancer Type: Kidney Cancer, Unknown Primary

NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults With AML or MDS
Cancer Type: Leukemia, Myelodysplastic Syndromes (MDS)

Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Cancer Type: Brain & Spinal Cord Tumor

Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations
Cancer Type: Bile Duct Cancer, Brain & Spinal Cord Tumor

Opaganib and Androgen Antagonists for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer
Cancer Type: Prostate Cancer

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Cancer Type: Leukemia, Myelodysplastic Syndromes (MDS)

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Cancer Type: Bile Duct Cancer, Breast Cancer, Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Stomach/ Gastric Cancer, Unknown Primary, Uterine Cancer

Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Bone Tumor, Prostate Cancer

Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cancer Type: Lung Cancer

Palbociclib with Cisplatin or Carboplatin in Treating Patients with Advanced Solid Tumors
Cancer Type: Breast Cancer, Lung Cancer, Pancreatic Cancer, Solid Tumor, Unknown Primary

Palliative Care with Dignity Therapy in Supporting Elderly Patients with Cancer
Cancer Type: Unknown Primary

Paricalcitol and Hydroxychloroquine in Combination with Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer
Cancer Type: Pancreatic Cancer, Unknown Primary

PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
Cancer Type: Bile Duct Cancer

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Cancer Type: Skin Cancer (Non-Melanoma), Unknown Primary

Pembrolizumab and Hsp90 inhibitor XL888 in Treating Patients with Advanced Gastrointestinal Cancer
Cancer Type: Bile Duct Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Pancreatic Cancer, Small Bowel Cancer, Stomach/ Gastric Cancer

Pembrolizumab and Pralatrexate in Treating Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Pembrolizumab and Radiation Therapy in Treating Patients with Relapsed or Refractory Stage I-III Multiple Myeloma
Cancer Type: Multiple Myeloma

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients with Solid Tumors
Cancer Type: Solid Tumor

Pembrolizumab in Treating Patients with Recurrent Stage III-IVB Head and Neck Squamous Cell Cancer
Cancer Type: Head and Neck Cancer

Pembrolizumab with and without Intra-operative Radiation Therapy in Treating Patients with Triple Negative Breast Cancer
Cancer Type: Breast Cancer

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients with Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Cancer Type: Stomach/ Gastric Cancer

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Cancer Type: Colon/Rectal Cancer

Pepinemab with or without Ipilimumab or Nivolumab in Treating Patients with Stage I-III Pancreatic Cancer That Can Be Removed by Surgery or Stage IV Colorectal Cancer with Liver Metastasis That Can Be Removed by Surgery
Cancer Type: Colon/Rectal Cancer, Pancreatic Cancer

PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Cancer Type: Lung Cancer, Prostate Cancer , Unknown Primary

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Cancer Type: Leukemia

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Cancer Type: Colon/Rectal Cancer, Pancreatic Cancer, Sarcoma, Solid Tumor

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Cancer Type: Lymphoma, Solid Tumor

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells Specific in NY-ESO-1/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
Cancer Type: Lung Cancer

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients with IDH Mutant Grade II or III Glioma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor

Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor

Radiation Therapy with Durvalumab or Cetuximab in Treating Patients with Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Cancer Type: Head and Neck Cancer

Radiation Therapy with or without Cisplatin in Treating Patients with Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Cancer Type: Head and Neck Cancer

REtroperitoneal SArcoma Registry: an International Prospective Initiative
Cancer Type: Sarcoma

Rifaximin in Treating Patients with Monoclonal Gammopathy
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Riluzole in Reducing Central Nervous System Glutamate and Fatigue in Stage I-III Breast Cancer Survivors with High Inflammation
Cancer Type: Breast Cancer, Unknown Primary

Rituximab and Hyaluronidase Human in Treating Patients with Unresectable Stage III-IV Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Cancer Type: Melanoma

Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Cancer Type: Breast Cancer

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
Cancer Type: Head and Neck Cancer

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Siltuximab and Spartalizumab in Treating Participants with Metastatic Pancreatic Cancer
Cancer Type: Pancreatic Cancer, Unknown Primary

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study
Cancer Type: Sarcoma, Solid Tumor

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Cancer Type: Germ Cell Tumor

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5-15 Brain Metastases
Cancer Type: Brain & Spinal Cord Tumor, Unknown Primary

Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer
Cancer Type: Lung Cancer

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
Cancer Type: Gynecologic Cancers, Liver Cancer / Hepatoblastoma, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.
Cancer Type: Hematopoietic Malignancies, Leukemia, Multiple Myeloma, Myelodysplastic Syndromes (MDS)

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Cancer Type: Leukemia, Multiple Myeloma, Plasma cell neoplasm

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Cancer Type: Leukemia

Study of INBRX-105 in Patients With Solid Tumors
Cancer Type: Lung Cancer, Melanoma

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Cancer Type: Lung Cancer, Melanoma, Stomach/ Gastric Cancer

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Cancer Type: Breast Cancer, Colon/Rectal Cancer, Melanoma

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Cancer Type: Lymphoma

Study of Sacituzumab Govitecan-hziy in Metastatic Urothelial Cancer
Cancer Type: Unknown Primary

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type: Hematopoietic Malignancies, Multiple Myeloma, Non-Hodgkin Lymphoma

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Cancer Type: Solid Tumor, Unknown Primary

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
Cancer Type: Leukemia

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Cancer Type: Brain Tumor

SymptomCare@Home in Managing Symptoms for Participants with Cancer Receiving Chemotherapy and/or Immunotherapy
Cancer Type: Unknown Primary

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Talazoparib, Radiation Therapy, and Atezolizumab for the Treatment of gBRCA 1/2 Negative, PD-L1 Positive, Metastatic Triple-Negative Breast Cancer, TARA Study
Cancer Type: Breast Cancer

Talimogene laherparepvec before Surgery for the Treatment of High-Risk and Treatment-Naive Recurrent Melanoma
Cancer Type: Melanoma

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Bladder Cancer, Brain & Spinal Cord Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Plasma cell neoplasm, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Thyroid Cancer, Unknown Primary, Uterine Cancer

TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Cancer Type: Bile Duct Cancer

Telotristat Ethyl in Promoting Weight Stability in Patients with Recurrent Advanced Pancreatic Adenocarcinoma
Cancer Type: Pancreatic Cancer, Unknown Primary

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
Cancer Type: Head and Neck Cancer

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Cancer Type: Lung Cancer

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib alone in Recurrent or Refractory Endometrial Cancer following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
Cancer Type: Uterine Cancer

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type: Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer

Testing Whether Avoiding the Hippocampus During Whole-Brain Radiation Therapy Prevents Cognitive Side Effects in Patients with Small Cell Lung Cancer
Cancer Type: Lung Cancer

Testing Whether Treating Breast Cancer Metastases with Surgery or High-Dose Radiation Improves Survival
Cancer Type: Bone Tumor, Breast Cancer

THRIVE Breast Cancer App Study
Cancer Type: Breast Cancer, Unknown Primary

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Cancer Type: Multiple Myeloma

Trametinib with or without Dabrafenib Mesylate in Treating Patients with BRAF, KRAS, or NRAS Gene Mutation and Recurrent Multiple Myeloma
Cancer Type: Multiple Myeloma

Tremelimumab in Treating Patients with Previously Treated Metastatic Urothelial Cancer
Cancer Type: Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Cancer Type: Leukemia, Lymphoma, Non-Hodgkin Lymphoma

Ultrasound in Diagnosing Patients with Skin Lesions
Cancer Type: Unknown Primary

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Cancer Type: Breast Cancer

Vaccine Therapy in Preventing Recurrence in Patients with Her-2 Positive Stage I-III Breast Cancer
Cancer Type: Breast Cancer

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas
Cancer Type: Brain & Spinal Cord Tumor

Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer, SOLARIS Trial
Cancer Type: Colon/Rectal Cancer

VX15/2503 with or without Ipilimumab and/or Nivolumab in Treating Patients with Resectable Stage IIIB-D Melanoma
Cancer Type: Melanoma, Unknown Primary

Wild-Type Reovirus in Combination with Carfilzomib and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

Zinc Sulfate in Improving Quality of Life in Patients with Gastrointestinal Cancer That Cannot Be Removed by Surgery Who Are Receiving Chemotherapy
Cancer Type: Esophogeal Cancer, Liver Cancer / Hepatoblastoma, Pancreatic Cancer, Stomach/ Gastric Cancer
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.